Alphyn is developing Zabalafin Hydrogel as the first therapy to simultaneously tackle the interconnected drivers of AD
Clinical trial enrollment has long been a bottleneck in drug development
The plant can reach an annual capacity of 300 crore tablets and 90 crore capsules
These building blocks are essential to modern therapeutics, including fast-growing GLP-1 treatments for weight loss and diabetes
The FDA aims to make a decision by April 8, 2026
The companies aim to expand treatment options for millions living with metabolic disorders
The multi-partner team will integrate new technologies across the entire mAb production workflow, from cell line development to purification
The new centre brings advanced corneal procedures pioneered in India
LNK01006 is designed to deliver potent, selective inhibition of TYK2-mediated cytokine signaling with central nervous system exposure
Subscribe To Our Newsletter & Stay Updated
